Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82.
CAS
PubMed
Google Scholar
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
PubMed
PubMed Central
Google Scholar
Chen IJ, Jan Wu YJ, Lin CW, Fan KW, Luo SF, Ho HH, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639–46.
PubMed
Google Scholar
Hayashi S, Tanaka M, Kobayashi H, Nakazono T, Satoh T, Fukuno Y, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol. 2008;35(2):260–9.
PubMed
Google Scholar
Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985;28(3):249–55.
CAS
PubMed
Google Scholar
Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59(5):677–85.
PubMed
Google Scholar
Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther. 2018;20(1):7.
PubMed
PubMed Central
Google Scholar
Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev. 2014;13(10):1048–54.
PubMed
Google Scholar
De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70–4.
Google Scholar
Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013;34(3):117–30.
PubMed
PubMed Central
Google Scholar
Majhi S, Baral N, Lamsal M, Mehta KD. De Ritis ratio as diagnostic marker of alcoholic liver disease. Nepal Med Coll J. 2006;8(1):40–2.
PubMed
Google Scholar
Torkadi PP, Apte IC, Bhute AK. Biochemical evaluation of patients of alcoholic liver disease and non-alcoholic liver disease. Indian J Clin Biochem. 2014;29(1):79–83.
CAS
PubMed
Google Scholar
Darstein F, Hauser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, et al. Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: a real-world cohort. Clin Transpl. 2018;32(11):e13411.
Google Scholar
Rief P, Pichler M, Raggam R, Hafner F, Gerger A, Eller P, et al. The AST/ALT (De-Ritis) ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Medicine (Baltimore). 2016;95(24):e3843.
CAS
Google Scholar
Steininger M, Winter MP, Reiberger T, Koller L, El-Hamid F, Forster S, et al. De-Ritis ratio improves long-term risk prediction after acute myocardial infarction. J Clin Med. 2018:7(12). PMID 30477196.
Gao F, Chen C, Lu J, Zheng J, Ma XC, Yuan XY, et al. De Ritis ratio (AST/ALT) as an independent predictor of poor outcome in patients with acute ischemic stroke. Neuropsychiatr Dis Treat. 2017;13:1551–7.
CAS
PubMed
PubMed Central
Google Scholar
Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, et al. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015;194(1):30–5.
PubMed
Google Scholar
Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119(2):261–7.
CAS
PubMed
Google Scholar
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165(3):378–81.
PubMed
Google Scholar
McFadden RG, Oliphant LD. Serum lactate dehydrogenase in interstitial lung disease. Chest. 1991;100(4):1182.
CAS
PubMed
Google Scholar
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
CAS
PubMed
Google Scholar
Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.
PubMed
Google Scholar
An YS, Suh CH, Jung JY, Kim HA. Role of bone scan in the assessment of polymyositis/dermatomyositis. Clin Rheumatol. 2015;34(4):699–706.
PubMed
Google Scholar
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.
PubMed
Google Scholar
Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;47(6):858–64.
CAS
PubMed
Google Scholar
Zhong Z, Lin F, Yang J, Zhang F, Zeng X, You X. Pregnancy in polymyositis or dermatomyositis: retrospective results from a tertiary centre in China. Rheumatology (Oxford). 2017;56(8):1272–5.
Google Scholar
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000;46(12):2027–49.
CAS
PubMed
Google Scholar
Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol. 2016;30(1):149–68.
PubMed
Google Scholar
Radke JB, Algren DA, Chenoweth JA, Owen KP, Ford JB, Albertson TE, et al. Transaminase and creatine kinase ratios for differentiating delayed acetaminophen overdose from rhabdomyolysis. West J Emerg Med. 2018;19(4):731–6.
PubMed
PubMed Central
Google Scholar
Russell CD, Parajuli A, Gale HJ, Bulteel NS, Schuetz P, de Jager CPC, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis. J Inf Secur. 2019;78(5):339–48.
Google Scholar
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R et al: Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019, 54(3). PMID 31285305.
Schroder T, Fuchss J, Schneider I, Stoltenburg-Didinger G, Hanisch F. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32(3):148–53.
PubMed
PubMed Central
Google Scholar
Fujimoto K, Kubo K, Yamaguchi S, Honda T, Matsuzawa Y. Eosinophil activation in patients with pulmonary fibrosis. Chest. 1995;108(1):48–54.
CAS
PubMed
Google Scholar
Kovalszki A, Weller PF. Eosinophilia. Prim Care. 2016;43(4):607–17.
PubMed
PubMed Central
Google Scholar
Kuang FL. Approach to patients with eosinophilia. Med Clin North Am. 2020;104(1):1–14.
PubMed
PubMed Central
Google Scholar
Sheikh H, Siddiqui M, Uddin SMM, Haq A, Yaqoob U. The clinicopathological profile of eosinophilic myocarditis. Cureus. 2018;10(12):e3677.
PubMed
PubMed Central
Google Scholar
Abedin N, Seemann T, Kleinfeld S, Ruehrup J, Roseler S, Trautwein C et al: Fecal eosinophil cationic protein is a diagnostic and predictive biomarker in young adults with inflammatory bowel disease. J Clin Med 2019, 8(12). PMID 31756948.
Hozumi H, Fujisawa T, Enomoto N, Nakashima R, Enomoto Y, Suzuki Y, et al. Clinical utility of YKL-40 in polymyositis/dermatomyositis-associated interstitial lung disease. J Rheumatol. 2017;44(9):1394–401.
CAS
PubMed
Google Scholar
Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, et al. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther. 2017;19(1):9.
PubMed
PubMed Central
Google Scholar
Takanashi S, Nishina N, Nakazawa M, Kaneko Y, Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford). 2019;58(6):1034–9.
CAS
Google Scholar
Wang K, Zhao J, Chen Z, Li T, Tan X, Zheng Y, et al. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford). 2019;58(3):511–21.
CAS
Google Scholar
Jiang Z, Tao JH, Zuo T, Li XM, Wang GS, Fang X, et al. The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. Scand J Rheumatol. 2017;46(2):122–9.
PubMed
Google Scholar
Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford). 2019;58(12):2143–52.
Google Scholar
Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis. Arthritis Res Ther. 2015;17:27.
PubMed
PubMed Central
Google Scholar
Canat L, Ataly HA, Agalarov S, Alkan I, Altunrende F. The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma. Int Braz J Urol. 2018;44(2):288–95.
PubMed
PubMed Central
Google Scholar
Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019;19(1):841.
PubMed
PubMed Central
Google Scholar
Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22(2):245–50.
CAS
PubMed
Google Scholar
Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44(10):1282–6.
Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M, et al. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: data from the French pulmonary hypertension registry and review of the literature. Medicine (Baltimore). 2016;95(39):e4911.
Google Scholar
Yang X, Hao Y, Zhang X, Geng Y, Ji L, Li G, et al. Mortality of Chinese patients with polymyositis and dermatomyositis. Clin Rheumatol. 2020. PMID 31902027.